{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:54:10Z","timestamp":1772164450754,"version":"3.50.1"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01-CA097271"],"award-info":[{"award-number":["R01-CA097271"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Women with a history of ductal carcinoma in situ (DCIS) have an elevated risk of a subsequent invasive breast cancer, but there are few established potentially modifiable factors known to lower this risk. Bisphosphonates are a commonly used treatment for patients with osteoporosis and have been shown to lower risks of recurrence and mortality in patients with invasive breast cancer; however, their use has not previously been investigated within the context of DCIS. Utilizing a population-based nested case\u2013control design, we compared 301 cases of women diagnosed with DCIS and a subsequent breast cancer and 587 individually matched controls (on age, DCIS diagnosis year, primary treatment, histology, grade, and disease-free survival time) who were diagnosed with DCIS but never a subsequent breast cancer. Information on recency and duration of bisphosphonate use was ascertained from patient interviews and medical record reviews. Current users of bisphosphonates had a reduced risk of developing an invasive breast cancer compared with never users [OR = 0.50; 95% confidence interval (CI): 0.26\u20130.99]. Users of bisphosphonates for \u226548 months had a similar reduction in risk (OR = 0.45; 95% CI, 0.24\u20131.06). This is the first study to document that bisphosphonate use is associated with a lower risk of subsequent invasive breast cancer among women with a history of DCIS. This finding is consistent with the protective effect of bisphosphonates observed in other breast cancer settings. If validated by others, bisphosphonates may be an effective risk-reducing approach with the potential added benefits of its positive impacts on bone health and fracture risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study finds that bisphosphonate use among women with a history of DCIS is associated with lower risk of subsequent invasive breast cancer, providing a potential preventative approach for this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-20-4100","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T11:50:17Z","timestamp":1616586617000},"page":"2799-2802","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bisphosphonate Use and Breast Cancer Risk among Women with Ductal Carcinoma\n                    <i>In Situ<\/i>"],"prefix":"10.1158","volume":"81","author":[{"given":"Christopher I.","family":"Li","sequence":"first","affiliation":[{"name":"1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan R.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington."},{"name":"2Department of Surgery, University of Washington, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Tzu C.","family":"Tang","sequence":"additional","affiliation":[{"name":"1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-401X","authenticated-orcid":false,"given":"Peggy L.","family":"Porter","sequence":"additional","affiliation":[{"name":"3Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5643-6714","authenticated-orcid":false,"given":"Kathleen E.","family":"Malone","sequence":"additional","affiliation":[{"name":"1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"2022061706371058200_bib1","volume-title":"Cancer facts & figures 2013","author":"American Cancer Society","year":"2013"},{"key":"2022061706371058200_bib2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<392::AID-IJC14>3.0.CO;2-A","article-title":"Second cancers following in situ carcinoma of the breast","volume":"77","author":"Franceschi","year":"1998","journal-title":"Int J Cancer"},{"key":"2022061706371058200_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bjc.6603231","article-title":"Increased risk of second malignancies after in situ breast carcinoma in a population-based registry","volume":"95","author":"Soerjomataram","year":"2006","journal-title":"Br J Cancer"},{"key":"2022061706371058200_bib4","first-page":"495","article-title":"Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden","volume":"10","author":"Warnberg","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022061706371058200_bib5","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"key":"2022061706371058200_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jncimonographs\/lgq041","article-title":"Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials","volume":"2010","author":"Vogel","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2022061706371058200_bib7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1634\/theoncologist.2015-0310","article-title":"Tamoxifen initiation after ductal carcinoma in situ","volume":"21","author":"Nichols","year":"2016","journal-title":"Oncologist"},{"key":"2022061706371058200_bib8","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","article-title":"Oral bisphosphonate use and breast cancer incidence in postmenopausal women","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061706371058200_bib9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","article-title":"Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk","volume":"102","author":"Newcomb","year":"2010","journal-title":"Br J Cancer"},{"key":"2022061706371058200_bib10","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","article-title":"Use of bisphosphonates and risk of postmenopausal breast cancer","volume":"28","author":"Rennert","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022061706371058200_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"2022061706371058200_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/CLEP.S194056","article-title":"Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women","volume":"11","author":"Liu","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2022061706371058200_bib13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"key":"2022061706371058200_bib14","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/jnci\/djr399","article-title":"Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer","volume":"103","author":"Monsees","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2022061706371058200_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1055-9965.EPI-17-0837","article-title":"Family history and risk of second primary breast cancer after in situ breast carcinoma","volume":"27","author":"Baglia","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022061706371058200_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10552-018-1119-8","article-title":"Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma","volume":"30","author":"Baglia","year":"2019","journal-title":"Cancer Causes Control"},{"key":"2022061706371058200_bib17","doi-asserted-by":"crossref","first-page":"pky020","DOI":"10.1093\/jncics\/pky020","article-title":"Relationship between anthropometric factors and risk of second breast cancer among women with a history of ductal carcinoma in situ","volume":"2","author":"Flanagan","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"2022061706371058200_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12885-019-5379-9","article-title":"Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Cancer"},{"key":"2022061706371058200_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00223-019-00590-5","article-title":"Bone-bound bisphosphonates inhibit proliferation of breast cancer cells","volume":"105","author":"Park","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"2022061706371058200_bib20","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"key":"2022061706371058200_bib21","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022061706371058200_bib22","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res"},{"key":"2022061706371058200_bib23","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","article-title":"Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo","volume":"20","author":"Ottewell","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706371058200_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","article-title":"Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis","volume":"66","author":"Haider","year":"2014","journal-title":"Bone"},{"key":"2022061706371058200_bib25","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/jnci\/94.8.606","article-title":"Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies","volume":"94","author":"Key","year":"2002","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/10\/2799\/3082229\/2799.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/10\/2799\/3082229\/2799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:16:55Z","timestamp":1655482615000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/10\/2799\/665621\/Bisphosphonate-Use-and-Breast-Cancer-Risk-among"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,3,24]]},"published-print":{"date-parts":[[2021,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-4100","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6512448.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426779","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512448","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426779.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]}}}